Valeant Pharmaceutical International Inc.’s largest shareholder has staunchly defended the Canadian drugmaker, saying that Valeant is an aggressively-managed business that may push boundaries, but operates within the law. Investment firm Ruane, Cunniff & Goldfarb Inc. is the biggest investor in Valeant, with a nearly 10 percent stake.